With the wrap up of AMCP 2024 in New Orleans, we are thrilled to observe how the conference themes aligned so deeply with Clinakos Inc.‘s mission to better healthcare outcomes and patient care. The conference was a catalyst for progress and collaboration in advancing better therapies & patent outcomes, mirroring Clinakos’ relentless pursuit of advancing healthcare.

Throughout the conference, there were insightful presentations, especially from Satellite Symposia which tackled the use of bispecific antibodies in Non-Hodgkin’s Lymphoma, updates on Chronic Lymphocytic Leukemia management, keeping pace with new developments in Multiple Myeloma, novel therapies for metastatic breast cancer, and many more. These were supported by multiple biopharma companies including Bristol Myers Squibb, Takeda, Novartis, The Janssen Pharmaceutical Companies of Johnson & Johnson, Gilead Sciences, Sanofi, Regeneron, and others.

Kudos to all who contributed to the success of this remarkable gathering, including the esteemed speakers, dedicated attendees, and valued partners.

Together, let’s shape a healthier future for all!